Search

Displaying results 3461 - 3470 of 6198 in total
  1. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  2. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.

  3. Drug

    Silibinin

    go.drugbank.com/drugs/DB09298
    Investigational

    Silibinin is presented as a mixture of two diastereomers, silybin A and silybin B, which are found in an approximately equimolar ratio.

  4. Drug

    Diloxanide furoate

    go.drugbank.com/drugs/DB14638
    ApprovedInvestigational

  5. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial.

  6. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]

  7. Drug

    Ethylestrenol

    go.drugbank.com/drugs/DB01493
    ApprovedWithdrawn

    An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]

  8. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention

  9. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. … In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.

  10. Drug

    MBT-0312

    go.drugbank.com/drugs/DB05880
    Experimental

    MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.